David Weninger Barnes

This inventor holds 14 USPTO granted patents and 3 published patent applications and 3 EPO patents. Top assignee: Novartis Ag. Active years: 2010-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Weninger Barnes. Retrieved from https://idiyas.com/inventor/david-weninger-barnes

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 3)

% Patents Active = 50.0

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 14(Granted Patents)

Location History:

Cambridge, MA (US) (2014)
Waban, MA (US) (2010 - 2018)

Company Filing History:

14 out of 3,977

Novartis Ag

patents

Years Active: 2010-2018

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10112963 - Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (2018-10-30),

2. 9789118 - Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof (2017-10-17),

3. 9498483 - 2,3,5-trisubstituted thiophene compounds and uses thereof (2016-11-22),

4. 9480693 - Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (2016-11-01),

5. 9163040 - Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (2015-10-20),

6. 9102635 - Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy (2015-08-11),

7. 9040690 - 2,3,5-trisubstituted thiophene compounds and uses thereof (2015-05-26),

8. 8697739 - Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof (2014-04-15),

9. 8394858 - Cyclohexane derivatives and uses thereof (2013-03-12),

10. 8324239 - Furopyridine compounds and uses thereof (2012-12-04),

11. 8252820 - 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors (2012-08-28),

12. 8119666 - 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) (2012-02-21),

13. 8084448 - Organic compounds (2011-12-27),

14. 7700633 - Organic compounds (2010-04-20),

Title: **David Weninger Barnes: Innovator in Pharmaceutical Chemistry**

Introduction

David Weninger Barnes, a distinguished inventor located in Waban, MA, has made significant contributions to the field of pharmaceutical chemistry. With a total of 14 patents to his name, Barnes has been instrumental in the development of innovative compounds aimed at enhancing therapeutic treatments.

Latest Patents

Among his latest inventions are two notable patents. The first, titled "Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors," introduces a compound of formula I, or its pharmaceutically acceptable salt. This invention encompasses a method for manufacturing these compounds, outlining their therapeutic uses, along with pharmaceutical compositions that incorporate these compounds alongside other pharmacologically active agents.

His second recent patent, "Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof," provides compounds of formula (IV) or their pharmaceutically acceptable salts. This invention also describes a method for producing these compounds, detailing their therapeutic applications and combinations with other pharmacologically active agents, as well as relevant pharmaceutical compositions.

Career Highlights

David Barnes currently works at Novartis AG, a leading global healthcare company that focuses on innovative medicines. His role involves researching and developing new pharmaceutical solutions that address various medical needs, showcasing his dedication to advancing health through science.

Collaborations

Throughout his career, Barnes has collaborated with notable colleagues including Scott Louis Cohen and Gregory Raymond Bebernitz. These collaborations facilitate the sharing of knowledge and expertise, amplifying the potential impact of their combined research efforts in the pharmaceutical industry.

Conclusion

David Weninger Barnes exemplifies the spirit of innovation within the pharmaceutical sector. His patents not only reflect his technical expertise but also his commitment to improving health outcomes through effective therapeutic agents. With each new invention, Barnes continues to pave the way for advancements in medical treatments, marking him as a key contributor in his field.

Profile summary based on public USPTO records.